PLCD4: A Potential Drug Target and Biomarker (G84812)

Target Name: PLCD4

NCBI ID: G84812

PLCD4

PLCD4: A Potential Drug Target and Biomarker

Plasma cell kinase (PLCK) is a protein that is expressed in many different types of cancer cells, including leukemia, lymphoma, and multiple myeloma. It is involved in the process of cell growth, division, and survival, and has been implicated in the development and progression of these diseases. In recent years, researchers have become interested in investigating the potential therapeutic benefits of targeting PLCKs, with the hope of developing new treatments for these cancers.

One potential drug target that is being studied is PLCD4, which stands for plasma cell kinase delta-4. PLCK未-4 is a sphingomyelin phosphorylase that is involved in the production of sphingomyelin, which is a component of the cell membrane. It is found in many different types of cancer cells, including leukemia, lymphoma, and multiple myeloma.

Studies have shown that PLCK未-4 is often expressed in higher levels in cells that are more aggressive and have a shorter survival time. It is also associated with the development of resistance to chemotherapy, which is a common problem in these diseases.

In addition to its potential as a drug target, PLCK未-4 has also been shown to be a potential biomarker for some types of cancer. It is often measured in the blood or urine using techniques such as enzyme immunoprecipitation (EIP) or radioimmunoprecipitation (RIP). These methods can detect the presence of the protein in the samples, which can then be used to assess the level of PLCK未-4 and potentially identify patients who are more likely to respond to a particular treatment.

One of the challenges in studying PLCK未-4 as a potential drug target is its complex structure. It is a large protein that is involved in many different cellular processes, making it difficult to predict how it will interact with small molecules. Researchers have been able to identify some potential drug candidates that have been shown to interact with PLCK未-4, but more research is needed to identify the most effective and safe options.

Another challenge is the lack of understanding of the underlying biology of PLCK未-4. While it is known that it is involved in the production of sphingomyelin, it is not clear how this process contributes to the development and progression of cancer. Further research is needed to understand the full role of PLCK未-4 in these processes.

Despite these challenges, research into PLCK未-4 is ongoing, and there is hope that it will lead to the development of new and effective treatments for cancer.

Protein Name: Phospholipase C Delta 4

Functions: Hydrolyzes the phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 2 second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG mediates the activation of protein kinase C (PKC), while IP3 releases Ca(2+) from intracellular stores. Required for acrosome reaction in sperm during fertilization, probably by acting as an important enzyme for intracellular Ca(2+) mobilization in the zona pellucida-induced acrosome reaction. May play a role in cell growth. Modulates the liver regeneration in cooperation with nuclear PKC. Overexpression up-regulates the Erk signaling pathway and proliferation

The "PLCD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLCD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets